Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus
The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus
The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.
The main questions the study will answer are:
- Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?
- will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?
Researchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.
Participants will:
- provide recent HbA1c test results.
- then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.
- attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.
The GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.
研究概览
详细说明
This study is a randomized controlled split-mouth clinical trial that investigates the clinical, biochemical, and microbiological effects of adjunctive Hyadent BG® gel application into selected interproximal periodontal pocket sites after non-surgical periodontal treatment (NSPT) in patients with diabetes mellitus (DM) and stage III/IV periodontitis.
Periodontitis is a chronic inflammatory disease characterized by the progressive destruction of the tooth-supporting tissues. DM is an important modifying factor for periodontal disease progression and treatment response. Hyperglycemia-related alterations in host immune response, collagen metabolism, microvascular function, and wound healing may contribute to increased periodontal inflammation and delayed periodontal healing. Therefore, adjunctive local approaches that may enhance the response to NSPT are clinically relevant in this patient population.
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in periodontal tissues and the extracellular matrix. Because of its hydrophilic, viscoelastic, anti-inflammatory, and wound-healing properties, HA has been investigated as an adjunctive agent in periodontal therapy. In this study, HA gel will be applied locally into periodontal pockets after scaling and root planing to evaluate whether it provides additional benefit beyond NSPT alone.
The study will include a total of 23 patients with DM and Stage III/IV periodontitis who applied to the Department of Periodontology, Faculty of Dentistry, Marmara University. Eligible participants will receive detailed information regarding the study procedures, and written informed consent will be obtained prior to enrollment.
TREATMENT PROCEDURES
Before treatment, recent HbA1c and fasting plasma glucose (FPG) test results will be obtained. Two days before NSPT, radiographic and full-mouth clinical evaluations will be carried out to determine which jaw will be included in the study. Intraoral photographs will be taken, and impressions of the related jaw will be taken for stent fabrication. One day before NSPT, clinical measurements of the related sites with the stent will be repeated. NSPT will be completed in three sessions within two weeks. Before starting NSPT, baseline pooled gingival crevicular fluid (GCF) samples and then pooled subgingival microbiological samples will be collected sequentially from the related sites of the selected jaw. Then oral hygiene instructions will be provided, followed by full-mouth supragingival and subgingival scaling using ultrasonic and hand instruments in two weeks time. At the last session of NSPT, test sites (non-adjacent sites with ≥6 mm pocket depth) for adjunctive use of HA gel will be randomly determined by a toss of a coin from the selected jaw, and HA will be applied subgingivally.
All patients will be followed up at the 1-, 3-, and 6-month intervals.
Periodontal Clinical Measurements
At baseline and at 1, 3, and 6 months, full-mouth clinical measurements will be performed. Periodontal clinical measurements will be recorded at six sites per tooth-mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual-using a Williams periodontal probe (Hu-Friedy).
Plaque Index (PI): Dental plaque accumulation will be assessed after air drying the teeth using a periodontal probe and visual inspection, according to the PI system developed by Silness and Löe.
Gingival Index (GI): The gingival inflammatory status will be assessed using the GI developed by Löe and Silness.
Probing Depth (PD): PD will be measured as the distance from the free gingival margin to the base of the periodontal pocket by inserting the periodontal probe to the pocket base.
Clinical Attachment Level (CAL): CAL will be recorded by measuring the distance from the cemento-enamel junction to the base of the pocket.
Bleeding on Probing (BOP) (%): BOP will be assessed 25-30 seconds after pocket probing. Sites showing bleeding will be recorded as positive (+), while those without bleeding will be recorded as negative (-).
Collection of GCF and Subgingival Microbiological Samples At baseline, both GCF and pooled subgingival microbiological samples will be collected after clinical measurements from test and control sites, but at follow-up visits (1st, 3rd, and 6th months) prior to clinical measurements. Before sampling, supragingival plaque will be carefully removed, then the test (n=2) and control (n=2) sites will be isolated from saliva using cotton rolls and dried. First, GCF samples will be collected. Periopaper strips will be inserted 1-2 mm into the periodontal pocket and left in place for 30 seconds at the selected sites. GCF volume will be measured. Following GCF sampling, subgingival microbiological sampling will be carried out by inserting sterile paper points (#30) to the base of the periodontal pockets and kept in place for 10 seconds. All GCF and the subgingival microbiological samples will be stored at -80°C until the day of analysis. GCF samples will be analyzed for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels using commercially available enzyme-linked immunosorbent assay kits. IL-34 will be assessed as a marker related to local inflammatory activity, and β-CTX will be assessed as a marker of type I collagen degradation.
Quantification of A. actinomycetemcomitans, F. nucleatum, P. gingivalis, T. forsythia, and P. intermedia in subgingival microbiological samples will be performed using real-time polymerase chain reaction.
Statistical Analysis
Statistical analyses will be performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA). A confidence level of 95% will be adopted for all analyses, and a p value of less than 0.05 will be considered statistically significant.
Due to the split-mouth study design, test and control sites within the same individual will be treated as paired samples.
Descriptive statistics for clinical parameters (PI, GI, BOP, PD, and CAL) and biochemical markers (IL-34 and β-CTX) will be expressed as mean ± standard deviation, median, and minimum-maximum values.
The normality of data distribution will be assessed using the Shapiro-Wilk test. For normally distributed variables, within-group comparisons over time (baseline, 1 month, 3 months and 6 months) will be analyzed using one-way repeated measures analysis of variance (ANOVA). When a statistically significant difference is detected, pairwise comparisons will be performed using the Tukey post hoc test.
Comparisons between test and control sites will be conducted using the paired samples t-test.
For variables that do not follow a normal distribution, within-group comparisons over time will be analyzed using the Friedman two-way analysis of variance. When significant differences are observed, pairwise comparisons will be performed using the Wilcoxon signed-rank test.
Between-group comparisons for non-normally distributed variables will be performed using the Mann-Whitney U test.
Correlations between clinical, biochemical, and microbiological variables will be evaluated using Spearman's correlation analysis. Variables found to be significant will be further analyzed using multiple linear regression to assess their independent effects.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Basak Dogan
- 电话号码:+905332621170
- 邮箱:basakdogan@marmara.edu.tr
学习地点
-
-
-
Istanbul、土耳其(türkiye)
- Department of Periodontology, Faculty of Dentistry, Marmara University
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Individuals who sign the informed consent form
- Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)
- Participants without any systemic disease other than DM
- Participants diagnosed with Stage III or Stage IV periodontitis
- Nonsmokers
- Participants with at least 15 natural teeth present in the mouth (excluding third molars)
- Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement
Exclusion Criteria:
- Individuals who do not sign the informed consent form
- Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis
- Participants have received any periodontal treatment within 6 months prior to the study
- Participants who have used antibiotics within the last 3 months
- Smokers
- Participants who are pregnant or lactating
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Test
Non-surgical periodontal treatment and Hyaluronic Acid gel
|
洗牙和根面平整是牙周炎的常规金标准治疗方法。
作为此过程的一部分,去除龈下菌斑和牙垢并刨平牙根表面。
Hyaluronic acid will be locally applied to periodontal pockets as an adjunct to non-surgical periodontal therapy, aiming to support periodontal healing.
After completion of scaling and root planing, the material will be delivered subgingivally to designated test sites in a split-mouth design.
|
|
其他:Control
Non-surgical periodontal treatment alone
|
洗牙和根面平整是牙周炎的常规金标准治疗方法。
作为此过程的一部分,去除龈下菌斑和牙垢并刨平牙根表面。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Clinical Attachment Level
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Clinical attachment level (CAL) will be measured in millimeters using a periodontal probe.
The change in CAL will be calculated as the difference between baseline and follow-up measurements.
A decrease in CAL indicates an improvement in periodontal attachment.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in Probing Depth
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Probing depth will be measured around each tooth by recording the distance in millimeters from the gingival margin to the bottom of the pocket at 6 locations (mesiobuccal, mid-buccal, distobuccal, mesiopalatal, mid-palatal, distopalatal).
|
Baseline, 1, 3 and 6 months after NSPT
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change of Bleeding on Probing (%)
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Possible score for bleeding on probing range from %0 (no sites with bleeding on probing) to %100 (all sites with bleeding on probing).
Higher scores mean worse outcome.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in Plaque Index
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Possible scores for Plaque Index range from 0 (no plaque) to 3 (visible plaque all around the tooth).
Higher scores mean a worse outcome.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in Gingival Index
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Possible score for Gingival Index range from 0 (healthy gingiva) to 3 (severe gingivitis with bleeding).
Higher scores mean worse outcome.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in GCF IL-34 Levels
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in IL-34 levels from baseline to 1, 3 and 6 months after NSPT
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in GCF β-CTX Levels
大体时间:Baseline to 1, 3 and 6 months after NSPT
|
Change in β-CTX levels from baseline 1, 3 and 6 months after NSPT
|
Baseline to 1, 3 and 6 months after NSPT
|
|
Change in level of Porphyromonas gingivalis
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in Porphyromonas gingivalis levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in level of Fusobacterium nucleatum
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in Fusobacterium nucleatum levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in level of Aggregatibacter actinomycetemcomitans
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in A. actinomycetemcomitans levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in level of Tanerella forsythia
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in Tanerella forsythia levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
|
Baseline, 1, 3 and 6 months after NSPT
|
|
Change in level of Prevotella intermedia
大体时间:Baseline, 1, 3 and 6 months after NSPT
|
Change in Prevotella intermedia levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
|
Baseline, 1, 3 and 6 months after NSPT
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 09.2025.543
- TDH-2026-12438 (其他赠款/资助编号:Marmara University Scientific Research Projects Coordination Unit)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.